Verenium — Diversa — Jefferies 3rd Global Clean Technology Conference 2007
31 slides from Verenium's conference presentation, May 3, 2007
Slide 1: Jefferies 3rd Global Clean Technology Conference May 2, 2007
Jefferies 3 rd Global Clean Technology Conference May 2, 2007
Slide 2: Forward-Looking Statements
Forward-Looking Statements This discussion will include forward-looking statements that involve a high degree of risk and uncertainty. These include statements related to Celunol and/or Diversa's products, product candidates and business strategies, including for biofuels, the markets for Celunol an
Slide 3: Accelerating the Production of Cellulosic Biofuels: Company and Merger Overview
Accelerating the Production of Cellulosic Biofuels + Company and Merger Overview
Slide 4: Key Highlights: First fully-integrated cellulosic ethanol technology company
Key Highlights First fully-integrated cellulosic ethanol technology company • Superior operating platform – First company with end-to-end cellulosic ethanol capabilities • Deep, diversified product portfolio – Expertise in enzyme development combined with large-scale enzyme production • Blue-chip in
Slide 5: Diversa: Leader in High-performance Specialty Enzymes
Diversa: Leader in High-performance Specialty Enzymes Pioneer in the discovery and development of high-performance specialty enzymes Who is Diversa? Products/ Markets Achievements Strategy Leader in discovery & commercialization of proprietary enzymes Own world’s broadest array of enzymes Specialty
Slide 6: Diversa: Key Technologies
Diversa: Key Technologies 250+ issued patents and 500+ pending patents • Biodiversity – Unique access and patented approaches to capture nature’s enormous array of microbial biodiversity • DirectEvolution ™ Technologies – Multiple methods to optimize enzyme performance via laboratory evolution at th
Slide 7: Diversa: Focused Biofuels Strategy
Diversa: Focused Biofuels Strategy Celunol transaction complements series of preceding initiatives Jan 2006 Feb 2006 Mar 2006 Oct 2006 Dec 2006 Feb 2007 2 3 4 7 8 Diversa and Celunol announce intention to merge Jan 2007 Jan 2007 Focus on biofuels as part of strategic reorganization FDA approval of F
Slide 8: Keys to Success for a Cellulosic Ethanol Company
Keys to Success for a Cellulosic Ethanol Company • Critical First-Mover Advantages – Foundational process optimization and commercial expertise – Leading partner for complementary state-of-the-art technologies – Worldwide BD partner of choice – Magnet for world-class scientific and operational talen
Slide 9: Celunol: Leader in Emerging Cellulosic Ethanol Sector
Celunol: Leader in Emerging Cellulosic Ethanol Sector Leading technology, production and development capabilities Overview Asset Base Human Capital + IP Achievements • Founded in 1994 in Massachusetts • Exclusive rights to breakthrough cellulosic ethanol technology • First pilot plant in the US firs
Slide 10: Celunol: Proven Technologies
BW34 Cellulose (C6 Sugars) KO11 Hemicellulose (C5 Sugars) Exclusive worldwide rights to 2 uniquely designed micro-organisms Celunol: Proven Technologies BW34 Cellulose (C6 Sugars) Goal: High-yield, multi-feedstock, low-cost cellulosic ethanol production KO11 Hemicellulose (C5 Sugars) The Celunol Pro
Slide 11: Merger Rationale
Merger Rationale Diversa expertise Celunol expertise Diversa’s extensive enzyme capabilities + Celunol’s process and development expertise • Gene discovery • Enzyme development • Enzyme production • Operating assets • Proprietary processes • Project development • Opportunity to control the critical
Slide 12: Merger Terms
Merger Terms We are targeting a June 2007 closing Diversa shareholders to own 76%, Celunol shareholders 24% Pro Forma Ownership: Diversa to issue 15 mm shares of Diversa stock Consideration: Timeline: Diversa to provide $20mm in debt funding for Celunol’s development efforts prior to closing Additio
Slide 13: Strategy and Competitive Advantages
Strategy and Competitive Advantages
Slide 14: Our Strategy: Five-point Foundation for Success
Our Strategy: Five-point Foundation for Success • First mover into cellulosic ethanol: – First mover into low-cost, multi-feedstock, commercial-scale cellulosic ethanol • Owner / operator of biofuels: – Develop, own and operate biofuels plants near low-cost feedstocks and refineries • Partnering / l
Slide 15: Combined Company Revenue Sources
Combined Company Revenue Sources Cellulosic Ethanol Sales Strategic Partnerships Biofuel Technology Licenses Specialty Enzyme Sales Multiple value opportunities across both businesses ENABLING TECHNOLOGY Enzyme Technology Licenses + • Enzyme Discovery & Optimization • Cellulosic Enzyme Cocktails • C
Slide 16: Biofuels Growth Strategy
Biofuels Growth Strategy Combined company expects 1st commercial-scale cellulosic ethanol facility in 2009 Pilot- Scale Demo-Scale 1.4 MGY First-Generation Commercial-Scale 25-30 MGY (bagasse) First-Generation Commercial-Scale 25-30 MGY (multiple feedstocks) Next-Generation Commercial-Scale 25-50+ M
Slide 17: First-Generation Prototypical Metrics
First-Generation Prototypical Metrics Preliminary estimates of key parameters for the 1 st commercial facility Likely sugarcane bagasse or other indigenous grasses to SE Feedstock: Southeastern US; most likely Louisiana or Florida Location: 25 to 30 MGY rated capacity Scale: Our Current Estimates fo
Slide 18: Superior Operating Platform
Superior Operating Platform Existing Diversa + Celunol platforms are highly complementary Co-products Multi-feedstock capable enzyme discovery + production 3 rd party technology licensing Corn Stover Wood Chips Bagasse Switchgrass ethanol
Slide 19: How Do We Compare to the Competition?
R&D Infrastructure How Do We Compare to the Competition? Cellulosic Ethanol Demo Plant Cellulosic Ethanol Pilot Plant Blue-chip Partnerships Vertically Integrated Value Chain Unmatched combination of technology and operating expertise Flexible Multi- Feedstock Process Iogen Abengoa Broin Mascoma Not
Slide 20: Deep, Diversified Product Portfolio
Deep, Diversified Product Portfolio Many of Diversa’s products have already been successfully commercialized Markets Marketed Marketed In Development In Development Marketed Marketed Amylase - T Bayovac® - SRS Biofuels Industrial Processes Animal Health/ Nutrition Market Size Status >$150mm (U.S.) >
Slide 21: Future of Existing Enzyme Business
Future of Existing Enzyme Business Diversa will leverage its existing enzyme leadership to generate profitable revenues • Commercially augment and accelerate cellulosic ethanol production • Grow and sustain a profitable specialty enzyme business • Deploy enzyme technologies across diverse markets •
Slide 22: Blue-chip Industrial Partnerships
Blue-chip Industrial Partnerships Diversa has had a long history of partnerships with industry leaders Announced delivery (2005) of enzyme cocktail exceeding DOE performance targets Received $500,000 in milestone payments Enzyme cocktail for cellulosic ethanol (corn stover) Agreement to commercializ
Slide 23: Operating Track Record
Operating Track Record Management teams have delivered on their financial and strategic plans $3.0 $5.4 $9.8 $15.9 $0 $16 2003A 2004A 2005A 2006A Specialty enzyme product revenue growth ($MM)
Slide 24: Operating Track Record: Enzymes for Cellulosic Ethanol
Operating Track Record Diversa has considerable experience developing enzymes for cellulosic ethanol Cellulosic Enzymes from Termite Guts Integrated Corn Biorefinery New Zealand Biofuels Bagasse Conversion • Thousand of species sampled • Hundreds of new cellulases sequenced & patented • JGI working
Slide 25: Operating Track Record: Facility Status & Timing
DEMONSTRATION Facility Status & Timing Scientific Foundation Feedstocks Cost Structure Process Optimization Incremental Diversa Contribution LAB PILOT Scaleable, cost-efficient cellulosic ethanol production Operating Track Record Since 1994 Leading scientists in enzymes / cellulosic Multiple: Bagass
Slide 26: Market-Facing Business Areas
Market-Facing Business Areas Industry-leading pool of experience SPECIALTY ENZYMES BIOFUELS RESEARCH & DEVELOPMENT Enabling Platform
Slide 27: Financial Review
Financial Review
Slide 28: Our Financial Strategy
Our Financial Strategy Near-term (12 Months) Long-Term Additional Non-Equity Sources of Capital ¨ Completed $120 million convertible debt financing ¨ 3/31/07 cash balance: $126 million (excluding $20 million shoe) ¨ Federal governmental loan guarantees ¨ State governmental grants ¨ Royalties, milest
Slide 29: Project Financing Strategy
Project Financing Strategy $81 $81 $22 $39 Non-recourse debt financing to finance a majority of total construction costs $22 $5 $0 $20 $40 $60 $80 $100 $120 $140 First-Gen Next-Gen Company Equity Partner Equity Contribution Non-recourse Debt 35% Equity Cost ~$125 MM Each ($5/gal @ 25 MGY) 65% Non- R
Slide 30: Key Investment Considerations
Key Investment Considerations First fully-integrated cellulosic ethanol technology company • Superior operating platform – First company with end-to-end cellulosic ethanol capabilities • Deep, diversified product portfolio – Expertise in enzyme development combined with large-scale enzyme production
Slide 31: Jefferies 3rd Global Clean Technology Conference May 2, 2007
Jefferies 3 rd Global Clean Technology Conference May 2, 2007
Diversa — Jefferies 3rd Global Clean Technology Conference 2007 on 6ix